Ask to take part

Contact the study team using the details below to take part. If there are no contact details below please ask your doctor in the first instance.

Contact Information:

George Naumov, PhD
(617) 835-5633

Study Location:

Skip to Main Content

Keep up to date

Sign up for news and information about taking part and shaping research.

English | Cymraeg
Be Part of Research - Trial Details - Study of RSO-021 in Patients With Malignant Pleural Effusion Due to Advanced/Metastatic Solid Tumors Including Mesothelioma

Study of RSO-021 in Patients With Malignant Pleural Effusion Due to Advanced/Metastatic Solid Tumors Including Mesothelioma


Open to: All Genders

Age: 18 Years - N/A

Medical Conditions

Malignant Pleural Effusion
Malignant Pleural Mesothelioma
Mesotheliomas Pleural
Pleural Effusion, Malignant

This information is provided directly by researchers and we recognise that it isn't always easy to understand. We are working with researchers to improve the accessibility of this information.

This is an open-label, non-randomized, multicenter, translational Phase 1/2 dose-escalation and expansion study designed to determine the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary anti-tumor activity of RSO-021 after intrapleural (IP) administration in patients with malignant pleural effusion (MPE) (non-mesothelioma) and MPE from mesothelioma.

Start dates may differ between countries and research sites. The research team are responsible for keeping the information up-to-date.  

The recruitment start and end dates are as follows:

Mar 2022 Apr 2025


Intervention Type : Drug
Intervention Description : A naturally-occurring, sulfur-rich, cyclic oligopeptide antibiotic of the thiopeptide class.

Intervention Arm Group : P2 - Dose Expansion - mesothelioma -First line treatment prior to Ipi/Nivo;Ph2 - Dose Expansion - MPE from mesothelioma;Ph2 - Dose Expansion - MPE from non-mesothelioma solid tumors;Ph2 - Dose Expansion - MPE from non-mesothelioma solid tumors combination with Paclitaxel;Phase 1 - Dose Escalation

You can take part if:

You may not be able to take part if:

This is in the inclusion criteria above

Below are the locations for where you can take part in the trial. Please note that not all sites may be open.

  • NHS Greater Glasgow & Clyde
  • Facility: HOPE Clinical Trials Facility, Leicester Royal Infirmary
    LE1 5WW
  • Barts Health NHS Cancer Institute
  • Guys and St Thomas NHS Foundation Trust
  • The Royal Marsden
    SW3 6JJ
  • The Christie NHS
  • Oxford University Hospitals NHS Foundation
  • South Mead North Bristol Hopsital
  • Leeds Teaching Hospital
  • Northumbria NorthTyne Side General Hospital
    North Shields
    NE29 8NH

The study is sponsored by RS Oncology LLC

We'd like your feedback

Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.

Is this study information helpful?

What will you do next?

Read full details for Trial ID: NCT05278975
Last updated 25 January 2024

This page is to help you find out about a research study and if you may be able to take part

You can print or share the study information with your GP/healthcare provider or contact the research team directly.